Gossamer Bio (GOSS) Competitors

Gossamer Bio (NASDAQ:GOSS) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Is GOSS or EVO more profitable?

Evotec's return on equity of 0.00% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	N/A	-127.28%	-22.12%
Evotec	N/A	N/A	N/A

Does the media prefer GOSS or EVO?

In the previous week, Gossamer Bio had 11 more articles in the media than Evotec. MarketBeat recorded 13 mentions for Gossamer Bio and 2 mentions for Evotec. Evotec's average media sentiment score of 0.96 beat Gossamer Bio's score of 0.49 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, GOSS or EVO?

Evotec has higher revenue and earnings than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$114.70M	2.30	-$179.82M	-$0.26	-4.46
Evotec	$777.05M	1.51	-$90.82M	N/A	N/A

Which has more volatility & risk, GOSS or EVO?

Gossamer Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Does the MarketBeat Community favor GOSS or EVO?

Gossamer Bio received 148 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 66.67% of users gave Gossamer Bio an outperform vote while only 54.55% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Gossamer Bio	Outperform Votes 154 66.67%	Underperform Votes 77 33.33%
Evotec	Outperform Votes 6 54.55%	Underperform Votes 5 45.45%

Do institutionals and insiders hold more shares of GOSS or EVO?

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend GOSS or EVO?

Gossamer Bio presently has a consensus price target of $7.75, suggesting a potential upside of 568.10%. Evotec has a consensus price target of $5.93, suggesting a potential upside of 78.71%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Gossamer Bio is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gossamer Bio beats Evotec on 10 of the 15 factors compared between the two stocks.